Roquinimex

Drug Profile

Roquinimex

Alternative Names: FCF 89; Linomide; LS 2616

Latest Information Update: 25 Sep 2006

Price : $50

At a glance

  • Originator Pfizer
  • Class Hydroxyquinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Diabetic complications; Gastrointestinal cancer; Hairy cell leukaemia; Leukaemia; Liver disorders; Malignant melanoma; Multiple sclerosis; Prostate cancer; Renal cancer; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 25 Sep 2006 Discontinued - Phase-I for Rheumatoid arthritis in European Union (PO)
  • 25 Sep 2006 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 25 Sep 2006 Discontinued - Preclinical for Prostate cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top